Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]
Antibiotics, 2023 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Arta Karruli +4 more
doaj +7 more sources
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review [PDF]
Antibiotics, 2022 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a
Luigi Principe +6 more
doaj +4 more sources
Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex [PDF]
PathogensCarbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease
Francesco Nappi
doaj +3 more sources
Low-dose sulbactam-durlobactam for recurrent CRAB pneumonia in a child with cerebral palsy: a Case Report from a resource-limited setting [PDF]
Frontiers in PharmacologyBackgroundPediatric data for sulbactam-durlobactam (SUL-DUR) are extremely scarce, and no standard pediatric dosing exists.MethodsWe report a 6-year-old boy with cerebral palsy and epilepsy who developed recurrent ventilator-associated pneumonia caused ...
Mengting Li +11 more
doaj +3 more sources
In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms [PDF]
Polish Journal of MicrobiologyThe management of carbapenem-resistant Acinetobacter baumannii (CRAB) infections remains a formidable clinical challenge. This study evaluated the in vitro antimicrobial activities of sulbactam-durlobactam (SUL-DUR) and eravacycline (ERV) against CRAB ...
He Xuelian +5 more
doaj +3 more sources
Resistance of Acinetobacter baumannii Complex Clinical Isolates to Sulbactam–Durlobactam: A Systematic Review of Data from In Vitro Studies [PDF]
PathogensIntroduction: Due to the limited therapeutic options for patients with Acinetobacter baumannii complex infections, a new combination antimicrobial agent, sulbactam–durlobactam, has been developed.
Matthew E. Falagas +3 more
doaj +3 more sources
Sulbactam/Durlobactam: First Approval
Drugs, 2023 Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with ...
Susan Keam (4873372)
openaire +3 more sources
Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 7, Page 396-402, July 2025.Abstract Background Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii ...
Wesley D. Kufel +8 more
wiley +3 more sources
Journal of Global Antimicrobial ResistanceObjective: Durlobactam, a diazabicyclooctane β-lactamase inhibitor, can protect meropenem from hydrolysis of KPC and OXA-48 carbapenemases. This study aims to characterise the genome of a carbapenem-resistant Klebsiella pneumoniae clinical strain with a ...
Hongxia Wen, Yu Feng, Zhiyong Zong
doaj +3 more sources
In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy [PDF]
Antibiotics, 2022 In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories.
Bernardetta Segatore +17 more
doaj +3 more sources